CAPR:NSD-Capricor Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 7.70

Change

+1.99 (+34.85)%

Market Cap

USD 0.12B

Volume

5.11M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002, a cardiac cell derived therapy, which is in phase II clinical trial for the treatment of patients with late-stage DMD; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. Capricor collaborates with Lonza for the development of CAP-1002, its cell therapy candidate for the treatment of Duchenne muscular dystrophy and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California. Address: 8840 Wilshire Boulevard, Beverly Hills, CA, United States, 90211

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+3.72 (+1.57%)

USD61.78B 23.28 18.31
REGN Regeneron Pharmaceuticals, Inc

+10.42 (+1.94%)

USD57.38B 19.71 15.20
MRNA Moderna, Inc

+15.98 (+12.20%)

USD51.85B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+1.59 (+1.00%)

USD34.94B 37.07 34.58
BGNE BeiGene, Ltd

+2.41 (+0.64%)

USD34.10B N/A N/A
SGEN Seagen Inc

-2.63 (-1.44%)

USD32.71B 69.01 69.56
RPRX Royalty Pharma plc

+0.34 (+0.66%)

USD31.99B 22.60 11.74
GMAB Genmab A/S

-0.36 (-0.84%)

USD28.33B 26.59 3.19
BNTX BioNTech SE

+2.17 (+2.00%)

USD26.11B -99,999.99 N/A
INCY Incyte Corporation

+2.61 (+2.67%)

USD21.44B 47.64 35.20

ETFs Containing CAPR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 124.49% 98% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 124.49% 98% A+ 98% A+
Trailing 12 Months  
Capital Gain 375.31% 95% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 375.31% 95% A 95% A
Trailing 5 Years  
Capital Gain -66.95% 24% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -66.95% 24% F 7% F
Average Annual (5 Year Horizon)  
Capital Gain -17.33% 19% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.33% 19% F 9% F
Risk Return Profile  
Volatility (Standard Deviation) 74.09% 34% F 15% F
Risk Adjusted Return -23.38% 28% F 22% F
Market Capitalization 0.12B 22% F 24% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 4.20 56% F 85% B
Price/Book Ratio 3.84 64% D 43% F
Price / Cash Flow Ratio -17.12 69% D+ 81% B-
EV/EBITDA 0.03 92% A- 98% A+
Management Effectiveness  
Return on Equity -64.44% 51% F 18% F
Return on Invested Capital -84.95% 32% F 11% F
Return on Assets -31.16% 42% F 12% F
Debt to Equity Ratio 49.36% 29% F 44% F
Technical Ratios  
Short Ratio 1.49 65% D 62% D-
Short Percent 3.80% 68% D+ 46% F
Beta 6.59 0% N/A 0% N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector